Pacific Biosciences Posts Higher Loss on Increased Costs, Reports $20M Backlog | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pacific Biosciences reported after the close of the market on Tuesday that it brought in revenues of $220,000 for the third quarter of 2010, compared to no revenues the previous year, as it prepares for a commercial launch of its single-molecule, real-time sequencing system.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.